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ABSTRACT
Background: Biomarkers of iodine status are required to study
iodine deficiency disorders in different parts of the world and to
evaluate the effects of fortification strategies.
Objective: The objective was to assess the usefulness of biomarkers
of iodine status in humans by systematically reviewing intervention
studies that altered iodine status.
Design: We performed a structured search for iodine intervention
studies on Ovid MEDLINE, EMBASE (Ovid), and the Cochrane
Library. Studies were assessed for inclusion and validity, with in-
dependent duplication. A random-effects meta-analysis was per-
formed.
Results: Twenty-one intervention studies (12 randomized con-
trolled trials, 3 controlled clinical trials, and 6 before-after studies)
were included in the review. Urinary iodine (in children and ado-
lescents and in those with low and moderate baseline iodine status),
thyroglobulin (in children and adolescents but not in pregnant and
lactating women), serum thyroxine (in children and adolescents,
adults, women, and those with moderate baseline thyroxine status
but not in pregnant and lactating women), and serum thyroid-
stimulating hormone (in pregnant and lactating women but not in
children and adolescents or those at moderate baseline status), but
not triiodothyronine, proved to be useful biomarkers of iodine status.
Conclusions: Despite the high risk of bias of many of the included
studies, the results suggested that urinary iodine, thyroglobin, serum
thyroxine, and thyroid-stimulating hormone are useful biomarkers
of iodine status, at least in some groups. High-quality controlled
studies measuring relevant long-term outcomes are needed to ad-
dress which biomarker is the most appropriate for assessing iodine
intake in some population groups and settings. Am J Clin Nutr
2009;89(suppl):2052S–69S.
INTRODUCTION
Iodine is an essential micronutrient for normal growth and
development. The human body contains ’15–20 mg of iodine, of
which 70–80% is concentrated in the thyroid gland. Iodine is
primarily obtained through the diet, but it is also a component of
some medications (1, 2).
Dietary iodine is converted into the iodide ion in the gut lumen,
and .90% is rapidly absorbed in the upper small intestine.
However, absorption can be reduced by the presence of goi-
trogens in some foods (including cabbage, broccoli, cassava, and
lima beans) and by deficiency of other micronutrients, such as
selenium (3, 4) or iron (5). Fifteen percent of ingested iodine is
taken up by the thyroid gland within 24 h of ingestion, and the
excess is excreted by the kidneys in urine (6).
The thyroid gland uses iodine for synthesis of the hormones
thyroxine and triiodothyronine, which are essential for mainte-
nance of the body’s metabolic rate by controlling energy pro-
duction and oxygen consumption in cells, for normal growth, and
for neural and sexual development (7). Thyroglobulin, the most
abundant thyroid protein, is a key precursor in the production of
thyroid hormones. The synthesis and release of thyroid hor-
mones are regulated by thyroid-stimulating hormone (TSH, or
thyrotropin), which is released from the pituitary gland into the
circulation. This regulation is subject to feedback inhibition.
Main sources of dietary iodine are iodized salt, saltwater fish,
seaweed, and grains, although only trace amounts are present in the
latter. The World Health Organization, International Council for
the Control of Iodine Deficiency Disorders (ICCIDD), and UNICEF
recommend daily iodine intakes of 90 lg/d for preschool children
and 150 lg/d for adults, reaching 250 lg/d for pregnant and
lactating women (8, 9). Despite remarkable progress in the control
of iodine deficiency disorders, they remain a significant global
public health problem (10). An estimated 200–300 million people
worldwide show some degree of iodine deficiency disorders (9),
especially in Asia and Africa but also in large parts of Eastern
Europe (11). These epidemiologic findings are surprising, con-
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sidering the very high efficiency of iodine recycling in human
metabolism. Severe iodine deficiency within populations leads to
endemic goiter, hypothyroidism, cretinism, decreased fertility
rates, increased infant mortality, and mental retardation. In adults,
iodine deficiency causes hypothyroidism and increased concen-
trations of TSH, causing hyperplasia of thyroid tissue, which re-
sults in goiter with iodine intakes ,50 lg/d.
Iodine can be added to salt as potassium iodide, potassium
iodate, or, less frequently, sodium iodide. Supplements vary in
iodine content and form and may be available as potassium iodide
tablets, prenatal multivitamin preparations, or iodized oil (12).
Iodine bioavailability is probably influenced by encapsulation
(tablets compared with gelatin capsules, coating substance, and
the amount of pressure used to form the tablets) (13); however,
only limited data are available. Although urinary iodine (UI)
reflects short-term changes (a few days) in intake, thyroid
function tests require 1 wk to respond (14, 15). Consequently,
for optimal assessment of iodine status, the minimum duration
of supplementation in intervention studies should be 2 wk.





Included studies needed to meet all of the following criteria: 1)
involve a human intervention; 2) be randomized or quasi-
randomized controlled trials (RCTs), nonrandomized studies
with a concurrent control group (controlled clinical trials;
CCTs), or before-after (B/A) studies; 3) report a change in io-
dine status over at 2 wk; 4) involve participants from any
population group, including children with goiter or populations
from iodine-deficient geographical regions; 5) involve supple-
mentation given as iodized salt (potassium iodide, potassium
iodate, or sodium iodide), iodized oil (given orally or by in-
jection), iodized water, iodine tablets, or iodine-enriched food or
milk formula; and 6) include a control group that was given
either a placebo (these studies were called RCT-1) or a low-dose
iodine supplement (RCT-2). In single-dose studies in which the
control group received a certain amount of iodine supplemen-
tation, the time period for data extraction was after the lower
dose was expected to be fully metabolized, ie, when there was
no residual impact on iodine status but while a potentially
measurable impact on iodine status after the higher dose was
still expected. For daily iodine supplementation, the low-dose
arm had to provide a dose ,100 lg iodine/d.
Search strategy
Ovid MEDLINE, EMBASE (Ovid; both at www.ovid.com), and
the Cochrane Library CENTRAL database (www.thecochranelibrary.
org) (from inception to September 2007) were searched for io-
dine intervention studies using text terms with appropriate
truncation, and relevant indexing terms were exploded when
relevant subterms needed to be included in the search. The
search was not limited to English language publications and was
in the form: [iodine terms] and [intervention study terms] and
[human studies]. The full-structured Ovid MEDLINE search
strategy can be found in Table S1 under ‘‘Supplemental data’’ in
the online issue. Search strategies for the other databases were
based on similar terms.
After an Ovid MEDLINE search, reviews of iodine status
methods were collected in full text (11, 16, 17), the reference
lists were checked (by DR-M and ZP), and the included study
list was updated accordingly; the proceedings of nutrition con-
ferences were also searched (18, 19). An expert in iodine me-
tabolism (Michael Zimmermann, Swiss Federal Institute of
Technology) was asked to check the included study list and to
suggest any additional studies.
Data collection
The methodology of this review is based on the standard
methodology developed for this set of reviews (20) and on methods
used by the Cochrane Collaboration (21). Briefly, titles and ab-
stracts were screened for inclusion independently by 3 reviewers
(DR-M, ZP, and MG). The full text of the articles collected were
screened for suitability with an inclusion/exclusion form used by
a single reviewer with an independent duplicate assessment of
a random sample of 50% by a second reviewer. Where the 2 re-
viewers disagreed, the study was discussed and a consensus de-
cision reached where possible. If this was not possible, then a third
reviewer was asked to arbitrate. Data were extracted onto a
Microsoft Access (Microsoft Corp, Redmond, WA) database file
by a single reviewer with independent duplicate assessment of
a random sample of 30% by a second reviewer. The form was
tested on 3 articles by each of the reviewers. If standard deviations
were not reported, they were calculated or estimated by using
methods described in the Cochrane Handbook (21).
Data synthesis
For each potential iodine status biomarker, we looked first at
the overall effect on iodine status through meta-analysis of the
FIGURE 1. Flow diagram for systematic review of biomarkers of
iodine status. UI, urinary iodine; Tg, thyroglobulin; T4, thyroxine; T3,
triiodothyronine; TSH, thyroid-stimulating hormone.
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TABLE 1
Characteristics of included studies on the effect of iodine supplementation on assessment of iodine status1
Study Population Intervention and control Outcomes reported Methodology





Age range: 4–16 y
Sex: male and female
Participant group: 69.8%
goiter rate in primary
school children baseline







dose 400 vs 200 mg
I/iodized oil capsules
Latest time point: 130 wk
No. in intervention at
latest time: 32
No. in control group at
latest time: 34
Analytic methods—UI:
catalytic action of iodide
through the reduction of
ceric ion by the oxidation




Study aim: to compare the
efficacy of 2 different
doses of oral iodized oil in
the treatment and
prophylaxis of goiter by
age and sex among school
children.
Comments: 42 wk used as
latest time point.




Age range: 20–38 y
Sex: female
Participant group:
pregnant women living in
marginally ID areas,
enrolled from the 10th to









Potassium iodide 200 vs
50 lg/d
Latest time point: 35 wk
No. in intervention at
latest time: 32








Study aim: to assess the
usefulness of iodine
supplementation in the























Latest time point: 52 wk
No. in intervention at
latest time: 32
Analytic methods—T4, T3,
TSH: RIA diagnostic kits.
Study design: B/A
Study aim: to investigate
the effect of iodized oil
administration on the
thyroid status of male
hypothyroid children and
adolescents residing in an
area of iodine deficiency.







Benmiloud_d (960 oral vs




Age range: 6–11 y
Sex: mixed
Participant group—children:









dose 120, 240, 480, 960,
mg iodine or 960 im
iodized poppy-seed oil
Latest time point: 395 d
No. in intervention at
latest time: 28









Study aim: to develop
better guidelines for
iodized oil, using 5
indicators to study
Algerian schoolchildren
given one of several doses
of iodized oil.





Age range: 9–16 y
Sex: mixed group
Participant group: baseline
iodine status median UI










dose 48 mg iodine/0.1 ml
iodized oil
Latest time point: 18 wk





IRMA; T4, T3, TSH:
RIA diagnostic kits
Study design: B/A
Study aim: to discusses
the causes of the
shortened response to
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TABLE 1 (Continued )
Study Population Intervention and control Outcomes reported Methodology
















dose 400 mg iodine/
iodized oil vs placebo
Latest time point: 4 mo
No. in intervention at
latest time: 122










Study aim: to present
effects of iodized poppy-
seed oil on cognitive and
motor function and
weight gain of iodine-
deficient schoolchildren.





Age range: 21–40 y
Sex: female
Participant group:
pregnant women, with no
clinical evidence of
autoimmune thyroid
disease; 14 had a history













Latest time point: 32 wk
No. in intervention at
latest time: 38
No. in control at latest
time: 70
Analytic methods—UI: Ce/




Study aim: the effects of
iodine supplementation




















single oral dose of iodized
oil 480 mg iodine (n ¼
73); iodine-2 single im
injection of iodized oil
480 mg iodine (n ¼ 71);
control-placebo capsule
(n ¼ 58).
Latest time point: 12 wk
No. in intervention at
latest time: 73
No. in control at latest
time: 58
Analytic methods—T4, T3:





Study aim: to compare
methods of iodine
supplementation, oral or
im, for their effectiveness
in reducing goiter and
improving thyroid







Age range: 15–44 y
Sex: female
Participant group: women
of reproductive age from
iodine deficiency region,







intervention: single oral or
im dose of 960 mg iodine/
2 ml iodized poppy-seed
oil or no treated group.
Latest time point: 96 wk
No. in intervention at
latest time: 130






blood disc was carried
out by the methods in
use in neonatal screening
Study design: CCT
Study aim: to compare
single doses of oral with
im iodized oil





24 wk after oral
supplementation of
Lipidol in women of
reproductive age, blood
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TABLE 1 (Continued )
Study Population Intervention and control Outcomes reported Methodology



















intervention: 0 (n ¼ 56),
50 (n ¼ 36) or 250
(n ¼ 34) lg potassium
iodide/d
Latest time point: 32 wk
No. in intervention at
latest time: 24















postpartum in an area of
mild iodine deficiency.
Comments: thyroid
hormone evaluated only at
the beginning of the study
in non-iodine-deficient
subjects.





Age range: 23–42 y
Sex: mixed
Participant group: healthy
and euthyroid, not obese,











iodine/d in form tablets vs
placebo.
Latest time point: 4 wk
No. in intervention at
latest time: 2





T3: RIA diagnostic kits;
TSH: IRMA
Study design: CCT
Study aim: to study the
effect of low-dose iodine
supplementation on
thyroid function before
and after the short-term
intake of a low-
carbohydrate diet in
normal subjects residing
in an iodine-deficient area.








premature infants (62 F,






intervention: 272 vs 68 lg
iodine/L milk formula.
Latest time point: 10 wk
No. in intervention at
latest time: 56













thyroid hormone levels in
preterm babies and hence
improve neuro-
developmental status.
Silva and Silva, 1981 (32)
Biomarkers measured:






pregnant women from an
iodine-deficient area,










daily of a 785-lg/mL KI
solution ’300 lg iodine/d
or not treated
Latest time point: 16 wk
No. in intervention at
latest time: 36
No. in control at latest
time: 10
Analytic methods—UI: Ce/
As method; T4, T3, TSH:
by RIA diagnostic kits
Study design: RCT-1





women as well as their
newborns.
(Continued)
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TABLE 1 (Continued )
Study Population Intervention and control Outcomes reported Methodology















iodine single dose in form
of potassium iodide.
Latest time point: 13 mo
No. in intervention at
latest time: 47





Study aim: to address how
often, and in what dose,
potassium iodide solution
should be given to achieve
effective prophylaxis of
iodine deficiency.
Tonglet et al, 1992 (33)
Biomarkers measured:
UI, T4, T3, TSH
Country: Zaire









dose 118 or 47 mg
iodine/d iodized oil
or placebo capsules
Latest time point: 48 wk
No. in intervention at
latest time: 25









Study aim: to study
efficacy of low doses of














30 girls) from an iodine-
deficient area; 20–60%








dose 540 mg/ml iodized
oil vs untreated
Latest time point: 10 mo
No. in intervention at
latest time: 99









Study aim: to evaluate the
suitability of indicators of
iodine status and thyroid
function, thyroglobulin,
TSH, and free thyroxine




















iodine/d vs 59 lg iodine/d
potassium food-like
tablets.
Latest time point: 23 wk
No. in intervention at
latest time: 31





Study aim: to compare the












Age range: 6–12 y
Sex: mixed
Participant group:
goitrous children in an









200 mg iodine/0.4 ml
iodized oil.
Latest time point: 50 wk










Study aim: to evaluate the
efficacy and safety of
a low dose of oral iodized
oil (0.4 ml) in goitrous
iodine-deficient children.
(Continued)
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interventiongroupcomparedwiththecontrolgroupforall included
studies that assessed the specified biomarker. For each iodine
supplementation study, we chose the longest time point at the
highest supplementationamount.Studiesweresubgroupedbytype
(RCTs, CCTs, or B/A studies) and meta-analysis was carried out
with RevMan 4.2 software (Copenhagen: The Nordic Cochrane
Centre, The Cochrane Collaboration) by using a random-effects
model. Tests for heterogeneity were carried out (I2) to assess the
variability between studies. We then addressed the secondary
questions as described in the main methodology article in this sup-
plement (20). Fixed-effect meta-analyses were used to check the
effect of the duration of supplementation on biomarker response.
RESULTS
The flow diagram for this review appears in Figure 1. We
screened 2019 titles and abstracts after the electronic and bib-
liographic searches. Of these, 60 appeared potentially relevant,
and 58 were collected as full-text papers (2 could not be traced)
and assessed for inclusion. Thirty-seven potential studies were
excluded (for reasons, see Figure 1). Twenty-one studies ful-
filled the inclusion criteria and reported on UI, thyroglobulin,
thyroxine, triiodothyronine, and/or TSH (16, 17, 22–40). Over-
all, 3172 participants were included in studies with a duration of
between 2 and 130 wk. Twelve of the studies were RCTs
(7 RCT-1 and 5 RCT-2), 3 CCTs, and 6 B/A studies. Eleven of
TABLE 1 (Continued )
























Latest time point: 10 mo








Study aim: to evaluate
the standardized
DBS-thyroglobulin assay
and reference range in
a longitudinal study of
goitrous children before





























Latest time point: 52 wk














indicator of thyroid status
in schoolchildren before


















dose 400 mg iodine/
iodized poppy-seed oil vs
placebo
Latest time point: 24 wk
No. in intervention at
latest time: 134













and thyroid status and
affect their cognitive and
motor performance.
1 UI, urinary iodine; UIE, urinary iodine excretion; B/A, before-after study; DBS, dried blood spot; Ce/As method, reduction of ceric ion by the oxidation
of arsenite ion after acidic digestion method; DELFIA, immunofluorimetric assay; IRMA, immunoradiometric assay; RIA, radioimmunoassay; im, intra-
muscularly; KI, potassium iodide; RCT-1, randomized controlled trial with placebo; RCT-2, randomized controlled trial with low-dose iodine supplement;
CCT, nonrandomized studies with a concurrent control group; T4, thyroxine; T3, triiodothyronine; TSH, thyroid-stimulating hormone; Abuye_ a, male group;
Abuye_b, female group.
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TABLE 2
Validity of included studies1
Randomization
Intervention/dose
verificationStudy Randomized Method Dropouts/reason Compliance/method
Abuye et al, 1995 (22) Yes Stratified systematic
sampling





No Not stated Women with thyroid
disease
None mentioned Not mentioned
Azizi et al, 1996 (24) No Stratified by sex, age,
diagnostic criteria













No Not stated None mentioned None mentioned Not relevant/standard
pharmacologic
preparation
Huda et al, 2001 (38) Yes Not stated 11 in iodine group and 7











Yes According to the days the
women came to
pregnancy care unit
None mentioned Thyroid size
(ultrasonography)
Not mentioned












Yes Not stated 14 women reevaluated by
primary care










No Not stated None mentioned None mentioned Not relevant/standard
pharmacologic
preparation
Rogahn et al, 2000 (31) Yes Randomized number
tables
None mentioned None mentioned Standard milk formula
Silva and Silva,
1981 (32)





No Not stated None mentioned Side effects, thyroid size,
and height at 0 and 13
mo
Not reported





Pregnant women None mentioned Not relevant/standard
pharmacologic
preparation
van den Briel et al,
2001 (34)
Yes Stratified by school,
class, sex, and matched
for age and height
Left school or moved
from area





Yes Not stated Moved or refused blood
sample
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the studies were conducted in Africa, 6 in Europe, 3 in Asia, and
1 in South America. Participants were infants (2 studies), chil-
dren and adolescents (12 studies), or adults (7 studies). The
iodine supplement was iodized oil in 11 studies (22, 24, 25, 27,
28, 33–35, 37, 38, 40), potassium iodide in 7 (23, 26, 29, 30, 32,
38, 39), potassium iodate in 2 (16, 17), and iodide-enriched milk
formula in 1 study (31). Nine studies gave a daily dose of iodine
(in lg/d) and 12 gave a single dose (in mg). For further details of
the included studies, see Table 1.
Validity criteria are displayed in Table 2. Six of 12 RCTs had
unclear randomization methods. Dropouts varied greatly from
study to study, ranging from 7% to 60% (often increasing with
TABLE 2 (Continued )
Randomization
Intervention/dose
verificationStudy Randomized Method Dropouts/reason Compliance/method
Zimmermann et al, 2000
(35)








Zimmermann et al, 2006
(16)





a modification of the
Sandell-Kolthoff
reaction
Zimmermann et al, 2003
(17)
No Not stated None mentioned None mentioned Reagent-grade potassium
iodide was dry mixed
into local salt by using
a rotating drum mixer
at a concentration of
25 lg iodine/g salt. No
further dose
verification reported.











1 WHO, World Health Organization.
FIGURE 2. Primary analysis: urinary iodine (lg/L). WMD, weighted mean difference; RCT-1, randomized controlled trial with placebo; RCT-2,
randomized controlled trial with low-dose iodine supplement; Abuye_a, male group; Abuye_b, female group; Benmiloud_c, 960 vs 120 mg I.
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length of follow-up). Reasons for dropouts were given in only
7 studies, and compliance was discussed in 6 of the 21 studies.
Only 3 studies reported checking the iodine content of the sup-
plement. In 16 studies, iodine dose verification was not carried out
because the supplement was a standard pharmacologic preparation.
Urinary iodine
Iodine excretion was measured using different methods and in
a number of different units that could not always be interconverted
to allow comparison between studies (Table 1). Eleven studies
(16, 17, 22, 33–39) assessed change in UI status in response to
iodine supplementation. Meta-analysis of the highest-dose arms,
subgrouping by study design (3 RCT-1 studies, 4 RCT-2 studies,
and 4 B/A studies), showed a statistically significant effect of
supplementation on UI [weighted mean difference (WMD): 43.3
lg/L; 95% CI: 20.9, 65.8; 2012 participants; I2 ¼ 95%, P ¼
0.0002], with each study design suggesting a statistically signif-
icant effect (see Figure 2). This suggested that UI is a useful
biomarker of iodine status; because heterogeneity was high,
subgroup analysis was performed to assess the usefulness of UI in
infants (1 study), children and adolescents (9 studies), and adults
(1 study). UI is clearly a useful marker of iodine status in children
and adolescents (WMD: 50.3 lg/L; 95% CI: 24.2, 76.4; 1389
participants; I2 ¼ 96%), but its usefulness in other groups is
unclear due to the limited number of studies. This subgrouping
did not explain the original heterogeneity of effect (Table 3).
There were enough studies and participants to conclude that UI
is a useful biomarker in those with low (WMD: 55.2 lg/L; 95%
CI: 25.7, 84.71; 7 studies; 1012 participants; I2 ¼ 97%) (36, 38–
40, 42, 43) and moderate iodine status at baseline (WMD: 23.1
lg/L, 95% CI 7.0–39.1, 4 studies, 389 participants, I2 ¼ 0%)
(23, 37, 41). There were no studies of participants with high
baseline iodine status (Table 3).
Subgrouping by type of supplementation showed statistically
significant effects in both groups and did not reduce heterogeneity
(Table 3). Subgrouping by daily dose generally reduced the
number of studies in each category to ,3, but there was sufficient
evidence to suggest that UI appeared to be a useful biomarker of
iodine status in those given a ,500-mg single-dose of iodine but
not in larger single-dose studies. Ordering by duration of sup-
plementation did not suggest a significant effect of time on UI
response (Figure S1 under ‘‘Supplemental data’’ in the online
supplement). The analytic techniques used to determine UI ap-
peared to influence the data, with analysis using ammonium
persulfate seemingly associated with significant effects on UI but
TABLE 3
Systematic review subgrouping results for urinary iodine1
Analysis Mean effect, WMD (95% CI)
Study design
I2 Biomarker useful?2RCT CCT Before/after
lg/L no. of studies
included/no. of participants
%
All studies (primary outcome) 43.33 (20.88, 65.79) 7/784 N/A 4/617 94.9 Yes
Infants 18.00 (228.07, 64.07) 1/62 N/A N/A N/A Unclear
Children and adolescents 50.30 (24.22, 76.38) 5/772 N/A 4/617 95.9 Yes
Pregnant and lactating women N/A N/A N/A N/A N/A Unclear
Adults 6.33 (211.43, 24.09) 1/50 N/A N/A N/A Unclear
Postmenopausal women N/A N/A N/A N/A N/A Unclear
Elderly N/A N/A N/A N/A N/A Unclear
Low-income and immigrant groups N/A N/A N/A N/A N/A Unclear
Males 18.00 (26.47, 42.47) 2/128 N/A N/A 0 Unclear
Females 14.00 (234.20, 62.20) 1/63 N/A N/A N/A Unclear
Low status at baseline 55.18 (25.66, 84.71) 3/395 N/A 4/617 96.9 Yes
Moderate status 23.06 (7, 39.11) 4/389 N/A N/A 0 Unclear
High status N/A N/A N/A N/A N/A Unclear
Supplement: iodized oil 37.32 (19.73, 54.92) 6/976 N/A 1/104 81.6 Yes
Supplement: potassium iodide or iodate 59.53 (16.30, 35.36) 1/62 N/A 3/513 96.1 Yes
Dose
200 lg/d 7.86. (28.7, 24.2) 2/113 N/A N/A 0 Unclear
201–1000 lg/d 112.99 (13.03, 212.95) N/A N/A 2/460 92.30 Probably
1001 lg/d N/A N/A N/A N/A N/A Unclear
500 mg/single dose 41.87 (26.90, 56.85) 4/487 N/A 1/104 69.4 Yes
501 mg/single dose 30.22 (211.43, 1.87) 2/262 N/A 1/100 93.0 No
Analytic methods
With ammoniun persulfate 70.38 (37.72, 103.4) 2/343 N/A 3/564 90.0 Yes
With chloric acid 12.31 (27.15, 31.77) 3/327 N/A 1/53 65.4 No
With automated Technicom Autoanalyzer 36.40 (224,54, 97.34) 2/114 N/A N/A 92.4 Unclear
1 WMD, weighted mean difference; RCT, randomized controlled trial; CCT, nonrandomized trial with a concurrent control group; N/A, no available data.
2 To claim that a biomarker was effective (ie, reflected a change in status) within a review, 3 conditions needed to be met: 1) statistical significance within
a forest plot (95% CI did not include 0 or P , 0.05), 2) 3 studies contributing data, and 3) 50 participants between the intervention and control arms
contributing data. To claim that a biomarker was ineffective, 4 conditions had to be met: 1) lack of statistical significance within a forest plot (95% CI included
0 or P  0.05), 2) 3 studies contributing data, 3) 50 participants between the intervention and control arms contributing data, and 4) study results were
roughly similar (heterogeneity levels were acceptable so that I2 ,50%).
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not analysis with chloric acid. There were insufficient studies
using an automated technicom analyzer to be sure of its effect.
Overall, UI appears to be an effective biomarker of iodine
status in children and adolescents, in those with low-to-moderate
baseline iodine status, in those supplemented with iodized oil and
potassium iodide or iodate, and in those given a single dose of
,500 mg iodine, whereas UI may not be a good marker of status
in those given higher (.500 mg) single doses of iodine. However,
the data were dependent on the analytic technique used, with
responses in UI shown when analysis was performed with am-
monium persulfate but not with chloric acid.
Serum thyroglobulin
Ten studies (16, 17, 23, 25, 26, 29, 30, 34, 37, 39) including
1569 participants showed a significant reduction of serum thy-
roglobulin concentration in response to iodine supplementation
(WMD: 212.8 ng/L; 95% CI: 222.9, 22.6, I2 ¼ 81%, P ¼
0.01), although there was significant heterogeneity in the data.
Subgrouping by RCTs, CCTs, and B/A studies did not reduce
heterogeneity greatly or suggest statistically significant effects
in any but the B/A studies (Figure 3). There was a significant
decrease in thyroglobulin concentration in children and adoles-
cents (WMD: 239.72 ng/L; 95% CI: 266.82, 212.62; 6 stud-
ies; 1324 participants; I2 ¼ 81%, P ¼ 0.004). The evidence was
unclear for other population subgroups except for pregnant and
lactating women, for whom there was evidence that the marker
was not effective (WMD: 21.29 ng/L; 95% CI: 27.67, 5.08;
I2 ¼ 43.0%; see Table 4). It appeared to be ineffective in adult
women (WMD: 21.2 ng/L; 95% CI:27.7, 5.1; 3 studies; 217
women; I2 ¼ 43.0%), but there was not enough evidence to
assess effectiveness in adult males. Thyroglobulin concentration
was not altered in response to supplementation in those with
moderate thyroglobulin baseline status (WMD: 23.5; 95%
CI: 27.9, 1.0; 6 studies; 648 participants; I2 ¼ 29%) but was
altered in those of high status (WMD: 281.5, 95% CI:
2150.7, 212.4; 4 studies; 348 participants; I2 ¼ 82%), with no
studies in those of low baseline status. Ordering studies by du-
ration of supplementation did not suggest an important time
effect on thyroglobulin (see Figure S2 under ‘‘Supplemental
data’’ in the online supplement). Subgrouping by supplementa-
tion type suggested that thyroglobulin is an effective biomarker
of iodized oil supplementation (WMD: 290.23 ng/L; 95%
CI: 2170.8, 29.65; 3 studies; 265 participants; I2 ¼ 88%) but
not of potassium iodate or iodide (WMD: 22.51 ng/L; 95%
CI: 25.53, 0.51; 7 studies; 758 participants; I2 ¼ 1%). Dose data
were confusing, with clear effects in the 201- to 1000-lg/d
subgroup, lack of effect in the 200-lg/d subgroup and
the .501-mg single-dose group, and unclear effects in other
groups (Table 4). Studies using immunofluoroimetric analytic
methods showed a significant effect on thyroglobulin, whereas
radioimmunoassay and immunoradiometric methods did not.
Thyroglobulin does appear to be a useful marker of iodine
status in children and adolescents, but there was little evidence of
its usefulness in other groups, and it does not appear to be useful
during pregnancy and lactation. Subgrouping did not clarify the
sources of heterogeneity in effect size, but the biomarker may be
more effective in populations with high baseline thyroglobulin
concentrations.
Serum thyroxine
Fourteen studies assessed the effect of iodine supplementation
on thyroxine (16, 17, 24–32, 35, 38, 40). Iodine supplementation
FIGURE 3. Primary analysis: serum/dried blood spot–thyroglobulin (ng/L). WMD, weighted mean difference; RCT-1, randomized controlled trial with
placebo; RCT-2, randomized controlled trial with low-dose iodine supplement; CCT, nonrandomized studies with a concurrent control group; Benmiloud_c,
960 vs 120 mg I.
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appears to increase thyroxine concentrations (WMD: 10.7; 95%
CI: 6.6, 14.7; 14 studies; 2459 participants; I2 ¼ 83%), and the
effect was similar regardless of the study methodology (Figure
4). There was evidence that thyroxine is a good marker of iodine
supplementation in children and adolescents (WMD: 14.0; 95%
CI: 7.4, 20.5; 8 studies; 1275 participants; I2 ¼ 93%) and adults
(WMD: 12.8; 95% CI: 2.3, 23.1; 3 studies; 260 participants;
I2 ¼ 85%) but not in pregnant and lactating women (WMD:
21.3; 95% CI: 20.8, 43.4; 3 studies; 204 participants; I2 ¼
68%), with too few studies in other groups to judge with any
certainty (Table 5). Thyroxine appears to be an effective bio-
marker in women (WMD: 19.9; 95% CI: 7.7, 32.1; 4 studies;
430 participants; I2 ¼ 52%), but there were insufficient studies
to evaluate the data in men.
Participants with a moderate thyroxine concentration at baseline
responded to iodine supplementation (WMD: 9.9; 95% CI: 5.6,
14.2; 12 studies; 1494 participants; I2 ¼ 84%), but there were
insufficient studies in those with low or high baseline status to draw
any conclusion. Iodized oil taken orally and potassium iodide or
iodate resulted in statistically significant thyroxine changes (P ,
0.0001), whereas there were insufficient studies to assess the ef-
fects of intramuscular iodized oil and supplemented infant formula
(Table 5).
A single dose (500 mg iodine) resulted in significant effects
on thyroxine (WMD: 10.5; 95% CI: 2.7, 18.3; 6 studies; 825
participants; I2 ¼ 90%, P ¼ 0.008), whereas a moderate daily
dose (201–1000 lg/d) did not (WMD: 6.8; 95% CI: 23.0, 16.6; 7
studies; 821 participants; I2 ¼ 93%), and there were insufficient
studies to assess other dose groups. Ordering studies by duration
had no clear effect on the size of the thyroxine response (Figure
S3 under ‘‘Supplemental data’’ in the online supplement).
Studies where thyroxine was assayed with both radioimmuno-
and immunofluorimetric assays resulted in significant effects on
thyroxine (Table 5).
Overall, serum thyroxine appears to be a useful marker of
iodine status in children and adolescents, adults, women, and
those at moderate thyroxine status at baseline, where iodized oil,
potassium iodate, or iodide are used for supplementation, where
a single dose of ,500 mg is given, and where either radio-
immuno- or immunofluorimetric assays are used. It is not a useful
biomarker in pregnant and lactating women or with moderate
daily supplementation. The significant heterogeneity seen in the
overall analysis of the usefulness of thyroxine is modulated by
separating out female only studies, supplementation with po-
tassium iodide or iodate, and use of radioimmunoassay kits.
Serum triiodothyronine
Eight studies assessed the effect of iodine supplementation on
triiodothyronine (24–27, 29–32). There was little evidence for
a statistically significant effect of changed iodine status on tri-
iodothyronine (WMD: 20.17 nmol/L; 95% CI: 20.36, 0.031;
TABLE 4
Subgrouping results for serum thyroglobulin1
Analysis Mean effect, WMD (95% CI)
Study design
I2 Biomarker useful?2RCT CCT Before/after
ng/L no. of studies
included/no. of participants
%
All studies (primary outcome) 212.75 (222.91, 22.59) 4/390 2/87 4/546 80.8 Yes
Infants N/A N/A N/A N/A N/A Unclear
Children and adolescents 239.72 (266.82, 212.62) 2/232 N/A 4/546 81 Yes
Pregnant and lactating women 21.29 (27.67, 5.08) 3/158 N/A 1/67 43.0 No
Adults 23.70 (210.73, 3.33) N/A N/A 1/20 N/A Unclear
Postmenopausal women N/A N/A N/A N/A N/A Unclear
Elderly N/A N/A N/A N/A N/A Unclear
Low-income and immigrant groups N/A N/A N/A N/A N/A Unclear
Males N/A N/A N/A N/A N/A Unclear
Females 21.29 (27.67, 5.08) 2/150 1/67 N/A 43.0 No
Low status at baseline N/A N/A N/A N/A N/A Unclear
Moderate status 23.47 (27.93, 0.98) 2/158 2/87 2/403 29.3 No
High status 281.53 (2150.71, 212.36) 2/232 N/A 2/116 81.7 Yes
Supplement: iodized oil 290.23 (2170.80, 29.65) 2/232 N/A 1/33 87.8 Yes
Supplement: potassium iodide or iodate 22.51 (25.53, 0.51) 2/158 2/87 3/513 0.7 No
Dose
200 lg/d 210.0 (221.71, 1.72) 1/62 2/55 N/A 66.2 No
201–1000 lg/d 214.19 (224.20, 24.17) 2/166 N/A 3/513 59.4 Yes
1001 lg/d 26.50 (217.69, 4.69) N/A N/A 1/53 N/A Unclear
500 mg/single dose 2222.00 (2312.99, 2131.01) N/A N/A 1/33 N/A Unclear
501 mg/single dose 225.25 (247.16, 3.35) 2/262 N/A 1/53 73.0 No
Analytic methods
Radioimunoassay 29.90 (223.3, 3.52) 3/354 N/A N/A 89.0 No
Immunoradiometric 252.95 (2130.37–24.46) N/A 2/87 1/33 91.2 No
Immunofluorimetric 213.76 (224.72, 22.80) 1/36 N/A 3/513 2.0 Yes
1 WMD, weighted mean difference; RCT, randomized controlled trial; CCT, nonrandomized study with a concurrent control group; N/A, no avail-
able data.
2 For explanation of terms, see Table 3, footnote 2.
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8 studies; 625 participants; I2 ¼ 86%) (Figure 5). There were
sufficient data to indicate that triiodothyronine is not a useful
biomarker of iodine status in children and adolescents, pregnant
and lactating women, females, and individuals with moderate
triiodothyronine status at baseline. Studies involving potassium
iodide or iodate supplementation in which participants consume
either a moderate daily iodine dose (201–1000 lg/d) or a500-mg
single dose or in which samples were analyzed by using either
radioimmuno- or immunofluorimetric assays also indicate that
triiodothyronine is not a useful biomarker (Table 6). In all other
subgroupings, there were insufficient studies to assess the effect
clearly. There was no evidence of an effect of duration on effect
size (Figure S4 under ‘‘Supplemental data’’ in the online sup-
plement). Overall, there is no evidence that triiodothyronine is
a useful biomarker for iodine status.
Serum thyroid-stimulating hormone
Sixteen studies assessed the effect of iodine intake on serum
TSH (16, 17, 23, 24, 26, 27, 29–35, 37–40), which, overall,
appeared to be a useful biomarker of iodine status (WMD:
23.00 mU/L; 95% CI: 24.59, 21.40; 16 studies; 1848 partic-
ipants; I2 ¼ 99.4%). However, the analysis demonstrated a high
degree of heterogeneity in the data, which can probably be ex-
plained by high baseline TSH status in participants from 2 of the
included studies (23, 24). Consequently, subgroup analysis was
undertaken in an attempt to identify other possible sources
of variability. RCT-1 studies showed a statistically significant
effect on TSH (WMD: 20.33 mU/L; 95% CI: 20.58, 20.08;
7 studies; 968 participants; I2 ¼ 29%, P , 0.01), but none of the
other methodology subgroups showed statistically significant
effects in their own right (Figure 6). There appeared to be
statistically significant reductions in TSH for pregnant and lac-
tating women (WMD: 28.8 mU/L; 95% CI: 214.9, 22.7;
4 studies; 184 participants; I2 ¼ 100%, P ¼ 0.005) but not for
children and adolescents (WMD: 20.26 mU/L; 95% CI: 20.78,
0.25; 9 studies; 1479 participants; I2 ¼ 81%), with insufficient
data in other participant groups to assess effectiveness. TSH
appeared to be a good marker of iodine status in females (data
for pregnant and lactating women), but there was insufficient
evidence in men (Table 7).
There was evidence that TSH was not an effective marker in
those with moderate TSH status at baseline (WMD: 20.15 mU/L;
95% CI: 20.4, 20.01; 14 studies; 1781 participants; I2 ¼ 67%),
and there was insufficient evidence from those with low or high
baseline status. TSH responded to supplementation with in-
tramuscular iodized oil (WMD: 23.38 mU/L; 95% CI:
26.69, 20.07; 3 studies; 205 participants; I2 ¼ 95%) and po-
tassium iodide or iodate (WMD: 25.07 mU/L; 95% CI:
28.57, 21.57; 7 studies; 658 participants; I2 ¼ 100%) but not
with oral iodized oil (WMD: 20.18 mU/L; 95% CI: 20.39,
0.03; 7 studies; 947 participants; I2 ¼ 11%) (unclear with sup-
plemented infant formula). There was evidence that a moderate
dose of daily iodine supplementation (201–1000 lg/d) did result
in reductions in TSH (WMD: 25.0 mU/L; 95% CI: 28.9, 21.1;
7 studies; 751 participants; I2 ¼ 100%), but a single dose of
,500 mg did not (WMD: 20.4 mU/L; 95% CI: 20.9, 0.2; 8
studies; 882 participants; I2 ¼ 85%), and results from other dose
groups were unclear. Ordering the meta-analyses by duration of
supplementation did not suggest any strong effect of duration on
TSH response (Figure S5 under ‘‘Supplemental data’’ in the
online supplement).
FIGURE 4. Primary analysis: serum thyroxine (nmol/L). WMD, weighted mean difference; RCT-1, randomized controlled trial with placebo; RCT-2,
randomized controlled trial with low-dose iodine supplement; CCT, nonrandomized study with a concurrent control group.
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TABLE 5
Subgrouping results for serum thyroxine1
Analysis Mean effect, WMD (95% CI)
Study design
I2 Biomarker useful?2RCT CCT Before/after
nmol/L no. of studies
included/no. of participants
%
All studies (primary outcome) 10.66 (6.63, 14.69) 7/873 2/250 5/629 90.9 Yes
Infants 2.00 (27.96, 11.96) 1/113 N/A N/A N/A Unclear
Children and adolescents 13.95 (7.41, 20.49) 3/656 N/A 5/619 93.2 Yes
Pregnant and lactating women 21.27 (20.83, 43.37) 3/204 N/A N/A 67.8 No
Adults 12.84 (2.28, 23.14) N/A 2/250 1/10 85 Yes
Postmenopausal women N/A N/A N/A N/A N/A Unclear
Elderly N/A N/A N/A N/A N/A Unclear
Low-income and immigrant groups N/A N/A N/A N/A N/A Unclear
Males 10.46 (29.82, 30.74) N/A N/A 1/32 N/A Unclear
Females 19.91 (7.74, 32.08) 3/204 1/226 N/A 52.1 Yes
Low status at baseline 41.25 (24.21, 86.70) N/A 1/226 1/32 96.4 Unclear
Moderate status 9.92 (5.62–14.22) 7/873 1/24 4/597 84,4 Yes
High status N/A N/A N/A N/A N/A Unclear
Supplement: iodized oil 11.76 (4.89, 18.62) 3/656 1/226 3/169 88.8 Yes
Supplement: iodized oil (im) 16.95 (29.58, 43.48) 1/129 1/168 N/A 93.7 Unclear
Supplement: potassium iodide or iodate 9.71 (4.28, 15.13) 3/280 1/24 2/460 69.6 Yes
Milk formula for preterm infants 2.00 (27.96, 11.96) 1/113 N/A N/A N/A Unclear
Dose
200 lg/d 215.39 (283.98, 53.20) 2/178 N/A N/A 96.8 Unclear
201–1000 lg/d 6.77 (23.03, 16.57) 4/337 1/24 2/460 92.5 No
1001 lg/d N/A N/A N/A N/A N/A Unclear
500 mg/single dose 10.51 (2.73, 18.29) 3/656 N/A 3/169 89.9 Yes
501 mg/single dose 18.60 (11.63, 25.57) N/A 1/226 N/A N/A Unclear
Analytic methods
Radioimunoassay 7.78 (3.13, 12.34) 3/438 1/24 2/65 63.5 Yes
Immunofluorimetric 12.17 (5.87, 18.47) 4/535 1/226 3/564 86.0 Yes
1 WMD, weighted mean difference; RCT, randomized controlled trial; CCT, nonrandomized trial with a concurrent control group; im, intramuscularly;
N/A, no available data.
2 For explanation of terms, see Table 3, footnote 2.
FIGURE 5. Primary analysis: serum triiodothyronine (nmol/L). WMD, weighted mean difference; RCT-1, randomized controlled trial with placebo; RCT-
2, randomized controlled trial with low-dose iodine supplement; CCT, nonrandomized study with a concurrent control group.
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Use of both immunoradiometric (WMD: 28.4 mU/L; 95%
CI: 215.3, 21.4; 4 studies; 438 participants; I2 ¼ 100%, P ¼
0.02) and immunofluorimetric assays (WMD: 20.20 mU/L;
95% CI: 20.37, 20.02; 6 studies; 992 participants; I2 ¼ 0%,
P ¼ 003) led to significant effects of iodine on TSH, but the 2
forms of assay gave very different results. The radioimmuno-
assay did not appear to be effective (WMD: 22.3 mU/L; 95%
CI: 24.7, 0.1; 4 studies; 192 participants; I2 ¼ 94%) (Table 7).
Overall, TSH appears to be a good marker of iodine status and
to be useful in pregnant and lactating women and females; with
intramuscular iodized oil, potassium iodide, or iodate; with
a moderate daily iodine dose; and when using immunoradio-
metric and immunofluorimetric assays. It does not appear to be
useful in children and adolescents, in persons with moderate TSH
baseline status who take oral iodized oil supplements or a single
dose of ,500 mg iodine, and when using radioimmunoassays for
sample analysis. There was little indication of which factors
might reduce the heterogeneity among studies.
DISCUSSION
Our meta-analyses have demonstrated that UI (in children and
adolescents and in those with low and moderate baseline iodine
status), serum thyroglobulin (in children and adolescents but not
in pregnant and lactating women), serum thyroxine (in children
and adolescents, adults, women, and those with moderate
baseline thyroxine status but not in pregnant and lactating
women), and TSH (in pregnant and lactating women and adult
females but not in children and adolescents or those at moderate
baseline TSH status) all seem to be useful biomarkers of iodine
status. However, there was no evidence that triiodothyronine is
a useful biomarker for iodine status.
Overall analysis of all the included studies confirmed UI as an
effective biomarker reflecting changes in iodine status in re-
sponse to iodine administration in certain circumstances. Serum
thyroglobulin is a promising new biomarker for monitoring
thyroid function (14, 40). However, its sensitivity in population
subgroups other than children and adolescents was unclear be-
cause of small numbers of participants in most subgroups, and
results were also inconsistent in pregnant and lactating women
(23, 26, 32). Two intervention studies (16, 17) used the novel
dried blood spot thyroglobulin assay and showed its sensitivity
to iodine status. It reflected improvements in thyroid function
within 42–52 wk of iodine repletion and seemed to be a valid
iodine deficiency disorder indicator in that it detected changes in
thyroid function in response to changes in iodine supply, which
was not shown with UI (33, 35).
The overall results of the meta-analysis showed a significant
increase in thyroxine concentration after supplementation;
however, there were many differences both between and within
TABLE 6
Subgrouping results for serum triiodothyronine1
Analysis Mean effect, WMD (95% CI)
Study design
I2 Biomarker useful?2RCT CCT Before/after
nmol/L no. of studies
included/no. of participants
%
All studies (primary outcome) 20.17 (20.36, 0.03) 5/4.71 1/24 2/65 86.3 No
Infants 20.41 (20.59, 20.23) 1/110 N/A N/A N/A Unclear
Children and adolescents 20.27 (20.62, 0.09) 1/131 N/A
2/55 86.9
No
Pregnant and lactating women 20.05 (20.25, 0.13) 3/230 N/A N/A 0 No
Adults 0.1 (20.02, 0.18) N/A 1/24 N/A N/A Unclear
Postmenopausal women N/A N/A N/A N/A N/A Unclear
The elderly N/A N/A N/A N/A N/A Unclear
Low-income and immigrant groups N/A N/A N/A N/A N/A Unclear
Males 20.60 (20.88, 0.32) N/A N/A 1/32 N/A Unclear
Females 20.06 (20.25, 0.13) 3/230 N/A N/A 0 No
Low status at baseline N/A N/A N/A N/A N/A Unclear
Moderate status 20.17 (20.36, 0.03) 5/471 1/24 2/65 86.3 No
High status N/A N/A N/A N/A N/A Unclear
Supplement: iodized oil 20.12 (20.47, 0.22) 1/131 N/A 1/33 82.8 Unclear
Supplement: iodized oil (im) 20.38 (20.79, 0.04) 1/129 N/A 1/32 83.9 Unclear
Supplement: potassium iodide or iodate 0.05 (20.06, 0.16) 3/230 1/24 N/A 14.7 No
Milk formula for preterm infants 20.41 (20.59, 20.23) 1/110 N/A N/A N/A Unclear
Dose
200 lg/d 20.30 (21.45, 2.05) 2/175 N/A N/A 88.3 Unclear
201–1000 lg/d 0.04 (20.59, 0.66) 4/346 1/24 N/A 87.8 No
1001 lg/d N/A N/A N/A N/A N/A Unclear
500 mg/single dose 20.27 (20.62, 0.08) 1/131 N/A 2/65 86.9 No
501 mg/single dose N/A N/A N/A N/A N/A Unclear
Analytic methods
Radioimunoassay 20.15 (20.39, 0.08) 2/203 1/24 2/65 92.8 No
Immunofluorimetric 20.19 (20.54, 0.15) 3/268 N/A N/A 71.9 No
1 WMD, weighted mean difference; RCT, randomized controlled trial; CCT, nonrandomized trial with a concurrent control group; im, intramuscularly;
N/A, no available data.
2 For explanation of terms, see Table 3, footnote 2.
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the population subgroups studied. A significant increase in serum
thyroxine concentrations after supplementation was shown in the
moderate thyroxine baseline status group. Many children had
goiter due to iodine deficiency even when their baseline thyroxine
concentrations were within the normal range. It is generally
accepted that thyroxine is usually not recommended for moni-
toring iodine status because of its lack of sensitivity; however, the
results of this review suggested that it may be a useful biomarker
in children and adolescents, females, and those with low-to-
moderate iodine status.
Random-effect analysis, which included all the studies, pre-
sented TSH as an effective biomarker for assessing change in
iodine status. Methods for determining TSH concentrations either
from dried blood spots on filter paper or from serum are well
established and widely available. Serum TSH is measured by
very sensitive and highly specific competitive radioimmuno-,
immunoradiometric, and immunofluorimetric assay methods,
which are available as commercial kits. However, in the case of
serum triiodothyronine, random-effects analysis did not show any
statistically significant change after supplementation; hence, it
cannot be considered as a suitable biomarker of iodine status.
Supplementation with iodized oil in studies measuring UI,
thyroglobulin, and thyroxine demonstrated a significant change
in status. Iodized oil, when given to children, showed statistically
significant changes in 4 of the biomarkers analyzed, which
proved the strong effectiveness of this form of supplementation in
this particular population subgroup. Further research is needed on
the effect of the oral and the intramuscular administration routes.
Some studies concluded that iodized oil injection improved
thyroid function and could be used for effective treatment of
goiter in children and adolescents (24, 27), but others suggested
that orally administered iodized oil is cheaper and simpler to use
and provides effective iodine prophylaxis for 2 y after a single
dose (28, 34).
Our systematic review included 21 studies, which combined
studies of different durations that assessed various doses with
various supplemental forms of iodine administered as daily
supplements or as single doses in different population subgroups
(including schoolchildren, pregnant women, and iodine-deficient
adults). These factors, coupled with each study’s specific aims
and study design, made comparison between the results some-
what complex. None of the included studies fulfilled all the ideal
quality criteria (Table 2); eg, there was imbalance in the ran-
domization process for some of the studies.
Cost-effectiveness was not assessed in any of the included
interventions, but it is an important factor that needs to be
addressed. For example, spot urine samples are relatively easy
and inexpensive to obtain, which makes UI a suitable assessment
method for iodine status in developing countries, compared with
thyroxine and triiodothyronine methods, which are expensive and
complex. The choice of the most appropriate indicators to assess
iodine status depends on several factors, including their per-
formance, available resources, the age or life stage of the sub-
jects, dietary patterns, the iodine status of the study group, and the
study objectives (18).
Because 90% of ingested iodine is excreted in the urine, UI
is a widely used method of assessment of iodine status and intake
(42). In this review, we found that UI is useful indicator of
iodine status along with thyroglobulin concentrations. In the
literature, thyroglobulin is described as a promising new
FIGURE 6. Primary analysis: serum thyroid-stimulating hormone (mU/L). WMD, weighted mean difference; RCT-1, randomized controlled trial with
placebo; RCT-2, randomized controlled trial with low-dose iodine supplement; CCT, nonrandomized study with a concurrent control group.
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biomarker for monitoring thyroid function (14, 15), which
seems to correlate with UI concentrations (9, 14, 41, 43). It is
also suggested that thyroid hormones are relatively insensitive
markers of status, although TSH is a sensitive biomarker in
newborns (14, 15, 44). In contrast, the current review showed
that TSH responded significantly to iodine supplementation in
the meta-analysis of included studies, although its effectiveness
in infants was unclear. The analysis of thyroxine concentration
also indicated its potential as a status biomarker. The results for
triiodothyronine were in accordance with the literature and
showed its ineffectiveness as a useful biomarker of iodine status.
To fully assess the validity of biomarkers of iodine status,
RCTs that measure relevant long-term outcomes that specifically
investigate iodine supplementation in various population groups
in a range of settings need to be undertaken. It is essential that the
studies use supplements of known iodine content and appropriate
analytic techniques for assessing biomarkers over2 time points.
However, interventions have often been carried out in areas with
a high prevalence of iodine deficiency, which makes placebo-
controlled groups ethically unfeasible. (Other articles in this
supplement to the Journal include references 20 and 45–51.)
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TABLE 7
Subgrouping results for serum thyroid-stimulating hormone1
Analysis Mean effect WMD (95% CI)
Study design
I2 Biomarker useful?2RCT CCT Before/after
mU/L no. of studies
included/no. of participants
%
All studies (primary outcome) 23.00 (24.59, 21.40) 10/1193 2/59 4/596 99.4 Yes
Infants 0.09 (20.28, 0.44) 1/111 N/A N/A N/A Unclear
Children and adolescents 20.26 (20.78, 0.25) 5/883 N/A 4/596 80.8 No
Pregnant and lactating women 28.80 (214.94, 22.65) 3/149 1/35 N/A 99.9 Yes
Adults 20.41 (22.56–1.74) 1/50 1/24 N/A 90.7 Unclear
Postmenopausal women N/A N/A N/A N/A N/A Unclear
Elderly N/A N/A N/A N/A N/A Unclear
Low-income and immigrant groups N/A N/A N/A N/A N/A Unclear
Males 233.60 (248.04 to 225.16) N/A N/A 1/32 N/A Unclear
Females 28.80 (214.94, 22.65) 3/149 1/35 N/A 99.9 Yes
Low status at baseline N/A N/A N/A N/A N/A Unclear
Moderate status 20.15 (20.38, 0.08) 10/1193 1/24 3/564 66.7 No
High status 233.84 (235.13, 232.54) N/A 1/35 1/32 0 Unclear
Supplement: iodized oil 20.18 (20.39, 0.03) 6/843 N/A 1/104 11.4 No
Supplement: iodized oil (im) 23.38 (26.69, 20.07) 2/173 N/A 1/32 94.7 Yes
Supplement: potassium iodide or iodate 25.07 (28.57, 1.57) 3/139 2/59 2/460 99.8 Yes
Milk formula for preterm infants 0.08 (20.28, 0.44) 1/111 N/A N/A N/A Unclear
Dose
200 lg/d 0.04 (20.40, 0.32) 2/163 N/A N/A 47.1 Unclear
201–1000 lg/d 24.97 (28.85, 21.09) 3/232 2/59 2/460 99.8 Yes
1001 lg/d N/A N/A N/A N/A N/A Unclear
500 mg/single dose 20.35 (20.92, 0.22) 6/746 N/A 2/136 84.9 No
501 mg/single dose 20.12 (20.39, 0.15) 1/74 N/A 1/104 0 Unclear
Analytic methods
Radioimunoassay 22.25 (24.65, 0.13) 3/160 N/A 1/32 93.6 No
Immunoradiometric 28.38 (215.33, 21.43) 2/379 2/59 N/A 99.9 Yes
Immunofluorimetric 20.20 (20.37 to 20.02) 3/428 N/A 3/564 0 Yes
Immunoluminescence 20.15 (20.40–0.09) 2/226 N/A N/A 0 Unclear
1 WMD, weighted mean difference; RCT, randomized controlled trial; CCT, nonrandomized trial with a concurrent control group; im, intramuscularly;
N/A, no available data.
2 For explanation of terms, see Table 3, footnote 2.
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